Press Release

India Human Papillomavirus Vaccine Market to be Led by Multinational Pharmaceutical Companies Through 2029

The increase in awareness about human papillomavirus vaccines among consumers is expected to drive the India human papillomavirus vaccine market during the forecast period.

According to the TechSci Research report, “India Human Papillomavirus Vaccine Market - By Region, Competition, Forecast, and Opportunities, 2029,” the human papillomavirus vaccine market in India is anticipated to grow at an impressive rate during the forecast periodThis can be ascribed due to the rising uptake of multi-valent human papillomavirus vaccines.

The India human papillomavirus vaccine market witnessed a substantial increase in the last few years. Multi-valent human papillomavirus vaccines are designed to protect against several strains of human papillomavirus, compared to the bivalent vaccine that protects against two human papillomavirus strains. The quadrivalent human papillomavirus vaccine and the nonvalent human papillomavirus vaccine are two multi-valent human papillomavirus vaccines that are currently available in India. These vaccines protect against more strains of human papillomavirus, including those that are associated with a higher risk of cervical cancer.
The uptake of multi-valent human papillomavirus vaccines in India has been driven by several factors, including increased awareness of the risks associated with cervical cancer, greater access to healthcare services, and the introduction of newer and more effective vaccines. The uptake of multi-valent human papillomavirus vaccines in this market is likely to continue to increase and help in the growth of this market in the years to come. Key trends in this market are emphasis on public-private partnerships and public-private partnerships, formed to develop and distribute HPV vaccines in India. This collaborative approach is expected to drive innovation, reduce costs, and increase access to these products over the forecast period.

Governments, NGOs, and healthcare organizations are working to increase access to HPV vaccines in India, especially in rural areas where healthcare infrastructure is limited. This includes various initiatives, such as mobile clinics, awareness campaigns, and subsidized vaccine programs.

Although the market for the human papillomavirus vaccine in India has been demonstrating an upward swing, the reluctance among patients for vaccines is a massive roadblock in the market’s otherwise positive growth trajectory. Some people are hesitant toward vaccination due to concerns about safety, efficacy, and potential side effects.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on the India Human Papillomavirus Vaccine Market

The India human papillomavirus vaccine market can be segmented by valence, disease indication, distribution channel, and region.

Based on disease indication, the market is segmented into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. This segment is expected to dominate the market during the forecast period as cervical cancer is the most common human papillomavirus-related cancer in India. The use of HPV vaccines has the potential to significantly reduce the incidence of cervical cancer. Private healthcare providers are also offering HPV vaccines in the country, which has further expanded access to these vaccines and reduced the chance of getting cervical cancer.
Based on the distribution channel, the market can be segmented into online markets and others. The segment is expected to dominate during the forecast period as the online market for human papillomavirus products and services is growing rapidly in India. With the increasing use of digital technology, patients are increasingly seeking information about their health online and are using e-commerce platforms to purchase health products. This trend is also seen in the human papillomavirus vaccine market, where patients are using online platforms to purchase HPV vaccines, diagnostic tests, and treatments.

Several online platforms offer human papillomavirus products and services in India, including e-pharmacies, online healthcare providers, and health and wellness portals. These platforms offer a convenient and accessible way for patients to access HPV-related products and services, particularly in remote or underserved areas where access to healthcare may be limited.
Furthermore, the COVID-19 pandemic accelerated the growth of online markets in the healthcare sector, especially the human papillomavirus vaccine market. Patients are increasingly turning to online platforms to purchase healthcare products and services, as social distancing measures and lockdowns have made it difficult for patients to access traditional healthcare facilities.

Major companies operating in the India Human Papillomavirus Market are:

  • Bharat Biotech International Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • MSD Pharmaceuticals Private Limited
  • Serum Institute of India Pvt. Ltd.
  •  HLL Lifecare Limited
  •  Panacea Biotec Ltd.


Recent Development

  • In 2020, MSD entered into a collaboration with Indian Immunological Limited (IIL) to expand access to Gardasil 9, a multi-valent HPV vaccine, in India. Under the collaboration, IIL will distribute the vaccine in India.
  • In 2019, Panacea Biotec announced a collaboration with SII to develop and manufacture a quadrivalent HPV vaccine. The vaccine is currently in clinical trials.

Download Free Sample Report

Customers can also request 10% free customization on this report.

“The India human papillomavirus vaccine market is expected to gain substantially from the rising in cancer cases caused by Papillomavirus, such as vulva cancer, vagina cancer, oropharynx cancer (back of throat including base of tongue and tonsils). Furthermore, this market is in its nascent stage and is expected to experience significant growth in the coming years. The inclusion of human papillomavirus vaccines in the national immunization program and the increasing awareness about cervical cancer prevention are likely to play an important role in driving the growth in this market. Besides, rising concerns about healthy lifestyles and increasing expenditure on health and wellness are further expected to create lucrative opportunities for the market’s growth over the forecast period,” said Mr. Karan Chechi, Research Director at TechSci Research, a research-based global management consulting firm.

India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), and By Region and Competition, Forecast & Opportunities, 2029 has evaluated the future growth potential of the India human papillomavirus vaccine market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the India human papillomavirus vaccine market.


Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]


Relevant News